Cannabis & Cannabinoids: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• WorkshopThe Role of Cannabis in Medicine

  Eden Evins · Jodi Gilman · Julia Arnsten · Randi Schuster

  Ticketed evening session examining the evidence for and against medical cannabis use.

• LectureIs Adolescent Cannabis Use a Causal Factor for Schizophrenia?

  Eden Evins

  Examines the evidence on whether cannabis use during adolescence contributes causally to schizophrenia.

  Child & AdolescentSchizophrenia & Psychosis

• LectureCannabis & Pain

  Julia Arnsten

  Reviews the role and evidence for cannabis in treating pain.

  Medical Comorbidity & C-L Psychiatry

• LectureNeuroscience of Cannabis

  Jodi Gilman

  Overview of how cannabis and cannabinoids act on the brain.

  Neuroscience & Mechanisms

• LectureClinical Trials of Cannabinoids for Insomnia, Pain, Anxiety, Depression

  Jodi Gilman · Eden Evins

  Summarizes clinical trial findings on cannabinoids for insomnia, pain, anxiety and depression.

  Anxiety DisordersDrug Pipeline & Clinical TrialsSleep & Insomnia

See all 7 cannabis & cannabinoids sessions at this meeting →

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• SessionCannabis Use and Early Psychosis Syndromes

  Elizabeth Cohen · Hyun Jung Kim · Tushita Mayanil · Henry Teaford · Jeonghyun Shin

  Clinical session on the relationship between cannabis use and early psychosis syndromes in youth.

  Child & AdolescentSchizophrenia & Psychosis

• LectureMary Jane 2.0: The Changing Face of Cannabis

  Elizabeth Cohen

  Talk on how cannabis products and use patterns are changing, within a session on cannabis and early psychosis.

  Child & AdolescentSchizophrenia & Psychosis

• LectureFrom High to Harm: Cannabis and the Neural Pathways Linked to Psychosis

  Henry Teaford

  Examines the neural pathways connecting cannabis use to psychosis risk.

  Neuroscience & MechanismsSchizophrenia & Psychosis

• LectureCannabis Use in Early Psychosis: Epidemiology, Risk Associations, and Evolving Practice Landscape

  Hyun Jung Kim

  Covers epidemiology and risk associations of cannabis use in early psychosis and how clinical practice is evolving.

  Schizophrenia & Psychosis

• LectureMind the Gap: Examining the Intersection of Cannabis Policy and Early Psychosis

  Jeonghyun Shin · Hyun Jung Kim

  Looks at how cannabis policy interacts with early psychosis care and outcomes.

  Practice, Policy & WorkforceSchizophrenia & Psychosis

See all 36 cannabis & cannabinoids sessions at this meeting →

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• SymposiumBeyond Abstinence: Measuring What Matters in Cannabis Use Disorder Medication Development

  Christina Brezing · Frances Levin · Margaret Haney · John Mariani

  Argues for moving beyond abstinence as the sole endpoint in cannabis use disorder trials, discussing reduction-based and patient-centered outcome measures.

  Drug Pipeline & Clinical TrialsSubstance Use Disorders

• WorkshopAnyone Can Treat! Building Confidence in Treating Youth Cannabis Use Disorder

  Gerald Busch · Ravi Shankar · Cathryn A. Galanter

  Builds general clinicians' confidence and skills in treating cannabis use disorder in adolescents.

  Child & AdolescentSubstance Use Disorders

• WorkshopFrom Plant to Patient: Navigating the Evidence, Risks, and Counseling of Medical Cannabis

  Elizabeth McCord · Yilang Tang · Karen Drexler · Michael Hsu

  Reviews the evidence base, risks, and patient-counseling approaches surrounding medical cannabis.

• WorkshopWhat Are You Smoking?: Addressing Nicotine and Cannabis Use in Adolescents

  Jennifer Creedon · Britney Lambert · Kimberly Rousseau

  Assessment and treatment strategies for nicotine and cannabis use among adolescents.

  Child & AdolescentSubstance Use Disorders

• SymposiumSymposium III - Beyond Abstinence: Measuring What Matters in Cannabis Use Disorder Medication Development

  Christina Brezing · Frances Levin · Margaret Haney · John Mariani

  Discusses moving cannabis use disorder trials and clinical care from abstinence-only endpoints toward reduction-based, patient-centered outcome measures.

  Drug Pipeline & Clinical TrialsSubstance Use Disorders

See all 17 cannabis & cannabinoids sessions at this meeting →

Substance Use Disorders: A Comprehensive Review and Update 2027

February 15–17, 2027 · Lake Buena Vista, FL

• LectureCannabis I

  Timothy E. Wilens

  First of two talks on cannabis in the context of substance use disorders.

• LectureCannabis II

  Robert R. Althoff

  Second talk in the cannabis module.

• PanelPanel Discussion

  Laura G. Kehoe · Timothy E. Wilens · Robert R. Althoff

  Panel discussion following the cannabis talks.

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• SymposiumS15 – Novel Therapies Symposium – showcasing clinical trials on emerging compounds and new medical devices

  Lone Baandrup · Viktoria Damgaard · Daniel Umbricht · Susan L. Rossell · Alexandra Philipsen · Mikołaj Matłoka

  Trial results on emerging treatments including cannabidiol vs risperidone for cannabis-related psychosis (CANRISE), a novel oral NMDA antagonist, PDE10A inhibition in schizophrenia, and digital devices.

  Drug Pipeline & Clinical TrialsSchizophrenia & Psychosis

Medical Psychiatry: Comprehensive Update Conference 2026

September 17–20, 2026 · Online

• CourseCounseling around the Use of Medical Cannabis

  Roxanne Sholevar

  On-demand mini-course on advising patients about medical cannabis.

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• SymposiumCannabis Use and Mental Illness: What We Now Know (and Don't)

  Ilan Melnick · Andrew Penn

  Updates clinicians on cannabis-induced psychosis, mood effects, and dose-response data amid rising THC potency, with practical tapering strategies and treatment pathways for cannabis use disorder.

  Schizophrenia & PsychosisSubstance Use Disorders